BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$157M+782.4% YoY

Gross Profit

$150M95.4% margin

Operating Income

-$178M-113.1% margin

Net Income

-$184M-117.1% margin

EPS (Diluted)

$-1.03

Cash Flow

Operating Cash Flow

-$142M

Free Cash Flow

-$145M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$588M

Total Liabilities

$695M

Stockholders' Equity

-$107M

Cash & Equivalents

$504M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$157M	$18M	+782.4%
Gross Profit	$150M	$16M	+829.0%
Operating Income	-$178M	-$175M	-1.7%
Net Income	-$184M	-$183M	-0.7%

BCRX FY 2021 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena